📊 VYGR Key Takeaways
Is Voyager Therapeutics, Inc. (VYGR) a Good Investment?
Voyager Therapeutics faces severe financial distress with a 49.5% revenue decline, operating losses exceeding $131.8M, and cash burn of $132.5M annually, leaving approximately 6 months of operational runway at current burn rates. While the balance sheet currently shows zero debt and reasonable liquidity, the deteriorating cash position combined with massive net losses and negative profitability margins indicates the company is unsustainable without significant operational turnaround or capital infusion.
Why Buy Voyager Therapeutics, Inc. Stock? VYGR Key Strengths
- Zero long-term debt with 0.00x debt-to-equity ratio reduces financial leverage risk
- Strong balance sheet with $196.1M stockholders equity and $65.3M cash position provides near-term liquidity cushion
- Exceptional current and quick ratios of 7.64x indicate ability to cover short-term obligations
VYGR Stock Risks: Voyager Therapeutics, Inc. Investment Risks
- Revenue declined 49.5% year-over-year, indicating deteriorating business fundamentals or failed commercialization
- Annual cash burn of $132.5M with only $65.3M cash provides approximately 6 months of operational runway before depletion
- Operating margin of -326.6% and net margin of -296.5% indicate business model is fundamentally unprofitable at current scale
Key Metrics to Watch
- Quarterly operating cash flow trend and remaining cash runway
- Revenue stabilization or recovery trajectory in next 2-3 quarters
- Capital raise announcements or reduction in operating burn rate
Voyager Therapeutics, Inc. (VYGR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.64x current ratio provides a solid financial cushion.
VYGR Profit Margin, ROE & Profitability Analysis
VYGR vs Healthcare Sector: How Voyager Therapeutics, Inc. Compares
How Voyager Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Voyager Therapeutics, Inc. Stock Overvalued? VYGR Valuation Analysis 2026
Based on fundamental analysis, Voyager Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Voyager Therapeutics, Inc. Balance Sheet: VYGR Debt, Cash & Liquidity
VYGR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Voyager Therapeutics, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.97 reflects profitable operations.
VYGR Revenue Growth, EPS Growth & YoY Performance
VYGR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $13.4M | -$9.0M | $-0.16 |
| Q2 2025 | $5.2M | -$10.1M | $-0.18 |
| Q1 2025 | $6.5M | -$11.3M | $-0.20 |
| Q3 2024 | $4.6M | -$9.0M | $-0.16 |
| Q2 2024 | $4.9M | -$10.1M | $-0.18 |
| Q1 2024 | $19.5M | -$11.3M | $-0.20 |
| Q3 2023 | $4.6M | $17.6M | $0.45 |
| Q2 2023 | $712.0K | -$19.1M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Voyager Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VYGR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Voyager Therapeutics, Inc. (CIK: 0001640266)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VYGR
What is the AI rating for VYGR?
Voyager Therapeutics, Inc. (VYGR) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VYGR's key strengths?
Claude: Zero long-term debt with 0.00x debt-to-equity ratio reduces financial leverage risk. Strong balance sheet with $196.1M stockholders equity and $65.3M cash position provides near-term liquidity cushion.
What are the risks of investing in VYGR?
Claude: Revenue declined 49.5% year-over-year, indicating deteriorating business fundamentals or failed commercialization. Annual cash burn of $132.5M with only $65.3M cash provides approximately 6 months of operational runway before depletion.
What is VYGR's revenue and growth?
Voyager Therapeutics, Inc. reported revenue of $40.4M.
Does VYGR pay dividends?
Voyager Therapeutics, Inc. does not currently pay dividends.
Where can I find VYGR SEC filings?
Official SEC filings for Voyager Therapeutics, Inc. (CIK: 0001640266) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VYGR's EPS?
Voyager Therapeutics, Inc. has a diluted EPS of $-2.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VYGR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Voyager Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VYGR stock overvalued or undervalued?
Valuation metrics for VYGR: ROE of -61.1% (sector avg: 15%), net margin of -296.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VYGR stock in 2026?
Our dual AI analysis gives Voyager Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VYGR's free cash flow?
Voyager Therapeutics, Inc.'s operating cash flow is $-132.5M, with capital expenditures of $2.6M. FCF margin is -334.5%.
How does VYGR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -296.5% (avg: 12%), ROE -61.1% (avg: 15%), current ratio 7.64 (avg: 2).